Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Above Fifty Day Moving Average – What’s Next?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s share price passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $6.24 and traded as high as $6.70. Karyopharm Therapeutics shares last traded at $6.47, with a volume of 248,256 shares.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Piper Sandler reiterated an “overweight” rating and issued a $12.00 price objective (down previously from $15.00) on shares of Karyopharm Therapeutics in a research note on Thursday, October 9th. HC Wainwright upgraded shares of Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Monday, October 13th. Robert W. Baird lowered their target price on Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, October 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $18.20.

Karyopharm Therapeutics Stock Performance

The stock has a market capitalization of $56.09 million, a P/E ratio of -0.44 and a beta of 0.34. The stock’s fifty day simple moving average is $6.24 and its two-hundred day simple moving average is $5.25.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Monday, August 11th. The company reported ($4.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.80) by ($0.52). The business had revenue of $37.93 million for the quarter, compared to analysts’ expectations of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. As a group, analysts expect that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Baird Financial Group Inc. bought a new stake in Karyopharm Therapeutics during the 2nd quarter worth approximately $45,000. XTX Topco Ltd bought a new stake in shares of Karyopharm Therapeutics in the 2nd quarter valued at $56,000. Bridgeway Capital Management LLC bought a new stake in shares of Karyopharm Therapeutics in the 2nd quarter valued at $163,000. Silverback Asset Management LLC boosted its stake in shares of Karyopharm Therapeutics by 40.0% in the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after purchasing an additional 20,000 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in shares of Karyopharm Therapeutics in the 1st quarter valued at $523,000. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).